vs
Hess Midstream LP（HESM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Hess Midstream LP的1.9倍（$772.1M vs $404.2M），Hess Midstream LP净利率更高（23.1% vs 12.7%，领先10.3%），Revvity同比增速更快（5.9% vs 2.1%），Hess Midstream LP自由现金流更多（$178.9M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 6.6%）
赫斯是美国全球化独立能源企业，主要从事原油与天然气的勘探、生产业务。公司于1968年由赫斯石油化工和阿美拉达石油合并成立，2023年10月同意被雪佛龙收购，相关交易已于2025年7月完成交割。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HESM vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$404.2M
营收增速更快
RVTY
高出3.8%
2.1%
净利率更高
HESM
高出10.3%
12.7%
自由现金流更多
HESM
多$17.1M
$161.8M
两年增速更快
RVTY
近两年复合增速
6.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $404.2M | $772.1M |
| 净利润 | $93.3M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 62.2% | 14.5% |
| 净利率 | 23.1% | 12.7% |
| 营收同比 | 2.1% | 5.9% |
| 净利润同比 | 32.5% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HESMRVTY
| Q4 25 | $404.2M | $772.1M | ||
| Q3 25 | $420.9M | $698.9M | ||
| Q2 25 | $414.2M | $720.3M | ||
| Q1 25 | $382.0M | $664.8M | ||
| Q4 24 | $395.9M | $729.4M | ||
| Q3 24 | $378.5M | $684.0M | ||
| Q2 24 | $365.5M | $691.7M | ||
| Q1 24 | $355.6M | $649.9M |
净利润HESMRVTY
| Q4 25 | $93.3M | $98.4M | ||
| Q3 25 | $97.7M | $46.7M | ||
| Q2 25 | $90.3M | $53.9M | ||
| Q1 25 | $71.6M | $42.2M | ||
| Q4 24 | $70.4M | $94.6M | ||
| Q3 24 | $58.6M | $94.4M | ||
| Q2 24 | $49.5M | $55.4M | ||
| Q1 24 | $44.6M | $26.0M |
毛利率HESMRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HESMRVTY
| Q4 25 | 62.2% | 14.5% | ||
| Q3 25 | 61.5% | 11.7% | ||
| Q2 25 | 62.8% | 12.6% | ||
| Q1 25 | 62.1% | 10.9% | ||
| Q4 24 | 61.4% | 16.3% | ||
| Q3 24 | 61.2% | 14.3% | ||
| Q2 24 | 60.8% | 12.4% | ||
| Q1 24 | 62.4% | 6.8% |
净利率HESMRVTY
| Q4 25 | 23.1% | 12.7% | ||
| Q3 25 | 23.2% | 6.7% | ||
| Q2 25 | 21.8% | 7.5% | ||
| Q1 25 | 18.7% | 6.4% | ||
| Q4 24 | 17.8% | 13.0% | ||
| Q3 24 | 15.5% | 13.8% | ||
| Q2 24 | 13.5% | 8.0% | ||
| Q1 24 | 12.5% | 4.0% |
每股收益（稀释后）HESMRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9M | $919.9M |
| 总债务越低越好 | $3.8B | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $4.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HESMRVTY
| Q4 25 | $1.9M | $919.9M | ||
| Q3 25 | $5.5M | $931.4M | ||
| Q2 25 | $4.5M | $991.8M | ||
| Q1 25 | $6.1M | $1.1B | ||
| Q4 24 | $4.3M | $1.2B | ||
| Q3 24 | $10.3M | $1.2B | ||
| Q2 24 | $99.6M | $2.0B | ||
| Q1 24 | $4.2M | $1.7B |
总债务HESMRVTY
| Q4 25 | $3.8B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HESMRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产HESMRVTY
| Q4 25 | $4.4B | $12.2B | ||
| Q3 25 | $4.4B | $12.1B | ||
| Q2 25 | $4.4B | $12.4B | ||
| Q1 25 | $4.3B | $12.4B | ||
| Q4 24 | $4.2B | $12.4B | ||
| Q3 24 | $4.1B | $12.8B | ||
| Q2 24 | $4.1B | $13.4B | ||
| Q1 24 | $3.9B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $245.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $178.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 44.3% | 21.0% |
| 资本支出强度资本支出/营收 | 16.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.63× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $728.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HESMRVTY
| Q4 25 | $245.6M | $182.0M | ||
| Q3 25 | $258.9M | $138.5M | ||
| Q2 25 | $276.9M | $134.3M | ||
| Q1 25 | $202.4M | $128.2M | ||
| Q4 24 | $258.5M | $174.2M | ||
| Q3 24 | $224.9M | $147.9M | ||
| Q2 24 | $271.6M | $158.6M | ||
| Q1 24 | $185.3M | $147.6M |
自由现金流HESMRVTY
| Q4 25 | $178.9M | $161.8M | ||
| Q3 25 | $178.9M | $120.0M | ||
| Q2 25 | $213.5M | $115.5M | ||
| Q1 25 | $156.9M | $112.2M | ||
| Q4 24 | $163.4M | $149.8M | ||
| Q3 24 | $132.6M | $125.6M | ||
| Q2 24 | $207.7M | $136.6M | ||
| Q1 24 | $130.5M | $129.7M |
自由现金流率HESMRVTY
| Q4 25 | 44.3% | 21.0% | ||
| Q3 25 | 42.5% | 17.2% | ||
| Q2 25 | 51.5% | 16.0% | ||
| Q1 25 | 41.1% | 16.9% | ||
| Q4 24 | 41.3% | 20.5% | ||
| Q3 24 | 35.0% | 18.4% | ||
| Q2 24 | 56.8% | 19.7% | ||
| Q1 24 | 36.7% | 20.0% |
资本支出强度HESMRVTY
| Q4 25 | 16.5% | 2.6% | ||
| Q3 25 | 19.0% | 2.6% | ||
| Q2 25 | 15.3% | 2.6% | ||
| Q1 25 | 11.9% | 2.4% | ||
| Q4 24 | 24.0% | 3.4% | ||
| Q3 24 | 24.4% | 3.3% | ||
| Q2 24 | 17.5% | 3.2% | ||
| Q1 24 | 15.4% | 2.7% |
现金转化率HESMRVTY
| Q4 25 | 2.63× | 1.85× | ||
| Q3 25 | 2.65× | 2.97× | ||
| Q2 25 | 3.07× | 2.49× | ||
| Q1 25 | 2.83× | 3.03× | ||
| Q4 24 | 3.67× | 1.84× | ||
| Q3 24 | 3.84× | 1.57× | ||
| Q2 24 | 5.49× | 2.87× | ||
| Q1 24 | 4.15× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HESM
| Gathering | $217.3M | 54% |
| Processing And Storage | $154.7M | 38% |
| Terminaling And Export | $32.2M | 8% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
